细胞凋亡在胰腺癌治疗中的作用

doi:10.11904/j.issn.1002-3070.2016.04.016

Abstract

Abstract: Pancreatic adenocarcinoma(PAC)is still a refractory human digest malignancies due to multifaceted causes,late diagnosis and insensitive to traditional chemo-and radio-therapy.Resistance to apoptosis could be one of the most relevant mechanisms for PAC to escape any non-surgical therapy.This review aims to clear up the main deregulated apoptosis signal pathways over the years and to find out the abnormal molecule target(s),and therefore,provide novel concepts for PAC molecular targeting therapy.

Key words: Apoptosis, Pancreatic cancer, Signal pathway, Target therapy

CLC Number:

R375.9

ZHAO Xiangxuan,WEN Feng,LU Zaiming. The role of apoptosis in pancreatic cancer therapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 375-379.

References

1 Lin QJ,Yang F,Jin C,et al.Current status and progress of pancreatic cancer in China[J].World J Gastroenterol,2015,21(26):7988-8003.
2 Arlt A,Muerkoster SS,Schafer H.Targeting apoptosis pathways in pancreatic cancer[J].Cancer Lett,2013,332(2):346-358.
3 Dao P,Smith N,Scott-Algara D,et al.Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor,PH11[J].Cancer Lett,2015,360(1):48-59.
4 Yu R,Albarenque SM,Cool RH,et al.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer[J].Cancer Biol Ther,2014,15(12):1658-1666.
5 Cristofanon S,Fulda S.ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells[J].Cell Death Dis,2012,3:e432.
6 Wang G,Zhan Y,Wang H,et al.ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein[J].Cancer Chemother Pharmacol,2012,69(3):799-805.
7 Murtaza I,Saleem M,Adhami VM,et al.Suppression of cFLIP by lupeol,a dietary triterpene,is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells[J].Cancer Res,2009,69(3):1156-1165.
8 Kim H,Buchsbaum DJ,Zinn KR.A novel imaging biomarker extracted from fluorescence microscopic imaging of TRA-8/DR5 oligomers predicts TRA-8 therapeutic efficacy in breast and pancreatic cancer mouse models[J].Mol Imaging Biol,2016,18(3):325-333.
9 Prabhu L,Mundade R,Korc M,et al.Critical role of NF-kappaB in pancreatic cancer[J].Oncotarget,2014,5(22):10969-10975.
10 Li F,Zhang J,Arfuso F,et al.NF-kappaB in cancer therapy[J].Arch Toxicol,2015,89(5):711-731.
11 Arlt A,Muerkoster SS,Schafer H.Targeting apoptosis pathways in pancreatic cancer[J].Cancer Lett,2013,332(2):346-358.
12 Lo M,Ling V,Low C,et al.Potential use of the anti-inflammatory drug,sulfasalazine,for targeted therapy of pancreatic cancer[J].Curr Oncol,2010,17(3):9-16.
13 Sirohi B,Singh A,Dawood S,et al.Advances in chemotherapy for pancreatic cancer[J].Indian J Surg Oncol,2015,6(1):47-56.
14 Nedaeinia R,Avan A,Manian M,et al.EGFR as a potential target for the treatment of pancreatic cancer:dilemma and controversies[J].Curr Drug Targets,2014,15(14):1293-1301.
15 Arnoletti JP,Frolov A,Eloubeidi M,et al.A phase I study evaluating the role of the anti-epidermal growth factor receptor(EGFR)antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer[J].Cancer Chemother Pharmacol,2011,67(4):891-897.
16 Strumberg D,Schultheis B,Scheulen ME,et al.Phase II study of nimotuzumab,a humanized monoclonal anti-epidermal growth factor receptor(EGFR)antibody,in patients with locally advanced or metastatic pancreatic cancer[J].Invest New Drugs,2012,30(3):1138-1143.
17 Boeck S,Jung A,Laubender RP,et al.EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer:translational results from the randomised,crossover phase 3 trial AIO-PK0104[J].Br J Cancer,2013,108(2):469-476.
18 Pan Y,Zheng M,Zhong L,et al.A preclinical evaluation of SKLB261,a multikinase inhibitor of EGFR/Src/VEGFR2,as a therapeutic agent against pancreatic cancer[J].Mol Cancer Ther,2015,14(2):407-418.
19 Huguet F,Fernet M,Giocanti N,et al.Afatinib,an irreversible EGFR family inhibitor,shows activity toward pancreatic cancer cells,alone and in combination with radiotherapy,independent of KRAS status[J].Target Oncol,2015,5(1):1-11.
20 Boeck S,Jung A,Laubender RP,et al.KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer[J].J Gastroenterol,2013,48(4):544-548.
21 Zheng H,Liu A,Liu B,et al.Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells[J].Cancer Lett,2010,297(1):117-125.
22 Roy SK,Srivastava RK,Shankar S.Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor,leading to cell cycle arrest and apoptosis in pancreatic cancer[J].J Mol Signal,2010,5(1):10-21.
23 Hao F,Kang J,Cao Y,et al.Curcumin attenuates palmitate-induced apoptosis in MIN6 pancreatic beta-cells through PI3K/Akt/FoxO1 and mitochondrial survival pathways[J].Apoptosis,2015,20(11):1420-1432.
24 Li W,Ma J,Ma Q,et al.Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-kappaB pathway[J].Curr Med Chem,2013,20(33):4185-4194.
25 Sharma N,Nanta R,Sharma J,et al.PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth[J].Oncotarget,2015,6(31):32039-32060.
26 Kristensen A,Vagnildhaug OM,Gronberg BH,et al.Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review[J].Crit Rev Oncol Hematol,2016,99(6):286-298.
27 Damaskos C,Karatzas T,Nikolidakis L,et al.Histone deacetylase(HDAC)inhibitors:current evidence for therapeutic activities in pancreatic cancer[J].Anticancer Res,2015,35(6):3129-3135.
28 Bauden M,Tassidis H,Ansari D.In vitro cytotoxicity evaluation of HDAC inhibitor apicidin in pancreatic carcinoma cells subsequent time and dose dependent treatment[J].Toxicol Lett,2015,236(1):8-15.
29 Minjie S,Defei H,Zhimin H,et al.Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase(HDAC)inhibitor ST-3595[J].Tumour Biol,2015,36(11):9015-9022.
30 Park SJ,Kim SM,Moon JH,et al.SAHA,an HDAC inhibitor,overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin[J].Tumour Biol,2015,54(3):1-8.
31 Hong L,Han Y,Li S,et al.The malignant phenotype-associated microRNA in gastroenteric,hepatobiliary and pancreatic carcinomas[J].Expert Opin Biol Ther,2010,10(12):1693-1701.
32 Srivastava SK,Bhardwaj A,Arora S,et al.MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and-independent pathways[J].Br J Cancer,2015,113(4):660-668.
33 Liu Z,Xu Y,Long J,et al.microRNA-218 suppresses the proliferation,invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1[J].Chin J Cancer Res,2015,27(3):247-257.
34 Guo R,Wang Y,Shi WY,et al.MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway[J].Molecules,2012,17(12):14733-14747.
35 Wang X,Wang L,Mo Q,et al.A positive feedback loop of p53/miR-19/TP53INP1 modulates pancreatic cancer cell proliferation and apoptosis[J].Oncol Rep,2016,35(1):518-523.
36 Azmi AS,Aboukameel A,Banerjee S,et al.MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function[J].Eur J Cancer,2010,46(6):1122-1131.
37 Camp ER,Wang C,Little EC,et al.Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy[J].Cancer Gene Ther,2013,20(4):222-228.
38 Izetti P,Hautefeuille A,Abujamra AL,et al.PRIMA-1,a mutant p53 reactivator,induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines[J].Invest New Drugs,2014,32(5):783-794.

[1]	LI Shan,ZHAO Chunbo,QIAO Wenbo. Progress in the application of intraoperative radiotherapy in pancreatic cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 280-283.
[2]	LUO Gan, YI Chao, YIMAMUMAIMAITIJIANGo Abula, XU Lin, YIN Jiwei, DING Wei. Expression of Notch signaling pathway in pancreatic cancer and its role [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 1-7.
[3]	SONG Ling, FU Qiong. Study of the effect of astragalin on proliferation of ovarian cancer cells by inhibiting the glycolytic pathway induced Via HIF-1α [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 503-509.
[4]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[5]	LI Yue, XU Ke, HAN Zengxiang, SUN Min, FAN Guohua, ZHANG Yong. Advances in the role of tumor-associated macrophage in colon cancer and targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 450-454.
[6]	LI Wenhui, LV Bowen, QIAN Jun, SU Liju, YANG Tongshu, QIAN Jingrong, WANG Jie. Effect of microRNA-150 on proliferation,apoptosis,invasion and metastasis of epithelial ovarian cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 208-213.
[7]	FAN Ningning, GENG Jingshu. The expression and role of LncRNA MEG3 in human glioma cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 219-223.
[8]	MENG Yongsheng. Effect of lycopene on the growth of human osteosarcoma cells and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 506-511.
[9]	CHEN Zhuo, KONG Yiran. Effect of silencing UHRF1 on proliferation and metastasis of breast cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 512-518.
[10]	LIANG Yusi, TAN Yonggang, ZOU Huawei. Research progress on mechanism of low-dose chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 538-542.
[11]	WANG Jixi, DENG Weisheng, WANG Fengru, SHI Zhimao, MENG Dan, XU Qiang, ZHANG Yuyao. Active part of Glycyrrhiza extract induces apoptosis in human cervical cancer HeLa cells and its related protein caspase-3 and caspase-9 expression [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 390-395.
[12]	HUANG Chenglu, HAN Shaohui, XU Suqin, ZHAO Jungang. The research progress of primary pulmonary mucinous adenocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 463-467.
[13]	LIU Qing,YOU Bosen,MA Jingguang,XING Lina. The expression and function of microRNA-30a in bladder cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 310-315.
[14]	ZHAO Menglei. Effects of lycopene on the proliferation and apoptosis in human hepatocellular carcinoma HepG2 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 211-216.
[15]	ZHANG Xuliang,HU Yahua,HUANG Danqing. Sulindac enhances sensitization effect of NF-κB on apoptosis induced by TNF-α in human breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 102-106.

The role of apoptosis in pancreatic cancer therapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments